For the Inventor, By the Inventor

Enter assignee name

Nijmegen, Netherlands

Synthon B.v.

USPTO Granted Patents = 89

% Expired Patents = 55.1

EPO Patents = 73

Trademarks = 1

Forward Citations = 275

Loading Chart...

Loading Chart...

75 inventors (with patents filed for the assignee):

Lisardo Alvarez Fernandez (15 out of 15 patents)

Jacobus Maria Lemmens (14 out of 21 patents)

Frantisek Picha (10 out of 18 patents)

4. Rohit Kumar (9 out of 9 patents)

5. Theodorus H A Peters (9 out of 17 patents)

6. Jose Velada Calzada (8 out of 8 patents)

7. Luis Nogueiras Nieto (8 out of 8 patents)

8. Marta Vivancos Martinez (7 out of 7 patents)

9. Jiri Bartl (7 out of 8 patents)

10. Rolf Keltjens (6 out of 9 patents)

11. Jie Zhu (6 out of 10 patents)

12. Arjanne Overeem (6 out of 8 patents)

13. Franciscus B G Benneker (6 out of 9 patents)

14. Marian Buchlovic (5 out of 5 patents)

15. Radomir Skoumal (5 out of 5 patents)

Core Competencies:

Apalutamide

Ozanimod

Bempedoic Acid

Pharmaceutical Composition

Axitinib

Palbociclib

Montelukast

Lenvatinib

Sugammadex

Venlafaxine

Ibrutinib

Tamsulosin

89 patents: Sort by Forward Citations

1. 12728096 - Pharmaceutical composition comprising enzalutamide (2026-09-08),

2. 12606539 - Process for preparation of apalutamide (2026-04-21),

3. 12570649 - Isavuconazonium salts and process for preparing thereof (2026-03-10),

4. 12528759 - Crystalline forms of bempedoic acid (2026-01-20),

5. 12522581 - Process for preparation of Axitinib (2026-01-13),

6. 12516013 - Crystalline forms of sodium salt of Bempedoic acid (2026-01-06),

7. 12410126 - Process for making Siponimod and intermediate thereof (2025-09-09),

8. 12409165 - Pharmaceutical composition comprising eltrombopag bis(monoethanolamine) (2025-09-09),

9. 12404256 - Process for preparing ozanimod (2025-09-02),

10. 12398112 - Crystalline form of ozanimod hydrochloride (2025-08-26),

11. 12290601 - Pharmaceutical composition comprising axitinib (2025-05-06),

12. 12240847 - Process for making palbociclib (2025-03-04),

13. 12102630 - Crystalline forms and processes of lenvatinib besylate (2024-10-01),

14. 11911509 - Pharmaceutical composition comprising Lenvatinib mesylate (2024-02-27),

15. 11865215 - Tablet compositions comprising abiraterone acetate (2024-01-09),

Company Overview

Synthon B.V., headquartered in Nijmegen, Netherlands, is a prominent player in the pharmaceutical industry, specializing in the development and manufacturing of innovative pharmaceutical compositions. The company focuses on a range of therapeutic areas, particularly in oncology and chronic diseases, with notable expertise in compounds such as Apalutamide, Ozanimod, and Bempedoic Acid. Synthon is dedicated to advancing healthcare through its commitment to research and development, aiming to provide high-quality, accessible treatments for patients worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

89 Patents

#2 in Nijmegen

#95 in Netherlands

#8,620 in the World

Nijmegen, Netherlands

Synthon B.v.

Forward Citations = 275

75 inventors:

Lisardo Alvarez Fernandez (15 out of 15 patents)

Jacobus Maria Lemmens (14 out of 21 patents)

Frantisek Picha (10 out of 18 patents)

4. Rohit Kumar (9 out of 9 patents)

5. Theodorus H A Peters (9 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Synthon B.v.. Retrieved from https://idiyas.com/company/synthon-b-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…